Table 1.
Characteristics of patients who underwent radical prostatectomy with or without neoadjuvant androgen-deprivation therapy.
| Variable | All (n = 711) | Neoadjuvant ADT |
P | |
|---|---|---|---|---|
| Not performed (n = 636) | Performed (n = 75) | |||
| Median age, y (IQR) | 66 (61–70) | 66 (61–70) | 67 (63–70) | 0.25 |
| Median PSA at diagnosis, ng/mL (IQR) | 7.9 (5.6–12.2) | 7.8 (5.5–11.9) | 10.3 (6.7–15.5) | 0.0013a) |
| NA | 7 | 4 | 3 | |
| Biopsy Gleason score, n (%) | ||||
| <7 | 251 (37.1) | 231 (37.7) | 20 (31.7) | |
| 7 | 309 (45.7) | 281 (45.8) | 28 (44.4) | |
| >7 | 116 (17.2) | 101 (16.5) | 15 (23.8) | 0.31 |
| NA | 35 | 23 | 12 | |
| Clinical T-stage, n (%) | ||||
| cT1/2a | 536 (81.6) | 487 (82.1) | 49 (76.6) | |
| cT2b | 46 (7.0) | 44 (7.4) | 2 (3.1) | |
| cT2c/3 | 75 (11.4) | 62 (10.5) | 13 (20.3) | 0.0025a) |
| NA | 54 | 43 | 11 | |
| Surgical procedures, n (%) | ||||
| Open RP | 317 (44.6) | 278 (43.7) | 39 (52.0) | |
| Laparoscopic RP | 92 (12.9) | 83 (13.1) | 9 (12.0) | |
| Robot-assisted RP | 302 (42.5) | 275 (43.2) | 27 (36.0) | 0.38 |
| Pathological Gleason score, n (%) | ||||
| <7 | 131 (21.3) | 131 (21.3) | — | |
| 7 | 425 (69.1) | 425 (69.1) | — | |
| >7 | 59 (9.6) | 59 (9.6) | — | NA |
| NA | 96 | 21 | 75 | |
| Pathological T-stage, n (%) | ||||
| pT0 | 12 (1.7) | 4 (0.6) | 8 (11.9) | |
| pT2 | 473 (68.7) | 427 (68.7) | 46 (68.7) | |
| pT3 | 199 (28.9) | 186 (29.9) | 13 (19.4) | |
| pT4 | 5 (0.7) | 5 (0.8) | 0 (0.0) | <0.0001a) |
| NA | 22 | 14 | 8 | |
ADT, androgen-deprivation therapy; IQR, interquartile range; NA, not available; PSA, prostate-specific antigen; RP, radical prostatectomy.
a)
Statistically significant.